The Bruton tyrosine kinase inhibitor acalabrutinib aborts ongoing acute food-induced anaphylactic reactions in humanized mice
Journal of Allergy and Clinical Immunology · 2025-11 · 156 (5) · 1277-1289
DOI: 10.1016/j.jaci.2025.07.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2025-11. Verfasst von Betania Arce und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Md. Hauptthemen laut MEDLINE: Anaphylaxis, Agammaglobulinaemia Tyrosine Kinase, Benzamides, Pyrazines. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH.
Abstract (Originalsprache)
BACKGROUND: There is a need for novel rescue therapies that can reduce morbidity and/or mortality from acute anaphylaxis. Given prior data showing that oral inhibitors of Bruton tyrosine kinase (BTK) can act rapidly as preventive agents for food-induced anaphylaxis in mice and humans, we hypothesized that these compounds could also abort ongoing acute IgE-mediated anaphylactic reactions. METHODS: Primary human mast cells and basophils were stimulated with anti-IgE, treated with the BTK inhibitor acalabrutinib, and assessed for activation and degranulation. NSG-SGM3 humanized mice with human mast cells and basophils were sensitized with human anti-Ara h 2 IgE and then orally challenged with peanut. After challenge, the mice received acalabrutinib and/or other rescue treatments via intraperitoneal injection. Anaphylactic response was assessed by core body temperature and clinical scoring. Mast cell and basophil mediators were measured in serum by ELISA at baseline and during anaphylaxis. RESULTS: Incubation of human mast cells and basophils with acalabrutinib after anti-IgE stimulation stopped ongoing activation as quickly as addition of the calcium chelator EDTA in vitro. Acalabrutinib completely prevented clinical reactivity to peanut in sensitized humanized mice when administered up to 2 minutes after challenge, with 100% survival versus 29% survival among the mice receiving vehicle control. Additionally, acalabrutinib synergized with epinephrine and formoterol in preventing mortality at 5 minutes after challenge. Serum prostaglandin D2 and leukotriene E4 levels were significantly decreased with acalabrutinib rescue treatment. CONCLUSIONS: Acalabrutinib can stop ongoing IgE-mediated anaphylaxis and prevent mortality in humanized mice. BTK inhibitors could be effective novel rescue medications when given in conjunction with epinephrine for the treatment of anaphylaxis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Md.
- Division of Allergy and Immunology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Tex.
- IgGenix, Inc, South San Francisco, Calif.
- Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill.
- Division of Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Md. Electronic address: mdispen1@jhmi.edu.
Förderung
- NIAID NIH HHS
- NIH
Zitieren
APA
Arce, B., Vilela, N. M., Chichester, K. L., Sokol, K. A., Alvarez-Arango, S., Iacobelli, L., Oliver, E. T., Croote, D., Bochner, B. S., MacGlashan, D. W., & Dispenza, M. C. (2025). The Bruton tyrosine kinase inhibitor acalabrutinib aborts ongoing acute food-induced anaphylactic reactions in humanized mice. Journal of Allergy and Clinical Immunology, 156(5), 1277-1289. https://doi.org/10.1016/j.jaci.2025.07.003
Vancouver
Arce B, Vilela NM, Chichester KL, Sokol KA, Alvarez-Arango S, Iacobelli L, et al. The Bruton tyrosine kinase inhibitor acalabrutinib aborts ongoing acute food-induced anaphylactic reactions in humanized mice. Journal of Allergy and Clinical Immunology. 2025;156(5):1277-1289. doi:10.1016/j.jaci.2025.07.003
BibTeX
@article{Arce2025,
author = {Arce, Betania and Vilela, Natalia M and Chichester, Kristin L and Sokol, Kristina A and Alvarez-Arango, Santiago and Iacobelli, Livia and Oliver, Eric T and Croote, Derek and Bochner, Bruce S and MacGlashan, Donald W and Dispenza, Melanie C},
title = {The Bruton tyrosine kinase inhibitor acalabrutinib aborts ongoing acute food-induced anaphylactic reactions in humanized mice},
journal = {Journal of Allergy and Clinical Immunology},
year = {2025},
volume = {156},
number = {5},
pages = {1277--1289},
doi = {10.1016/j.jaci.2025.07.003}
}
EUVIMED